{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:28:04Z","timestamp":1794356884131,"version":"4.9.0"},"reference-count":94,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"2","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Myelodysplastic syndrome (MDS) is considered to be a heterogeneous myeloid malignancy with a common origin in the hematopoietic stem cell compartment and is generally divided into lower- and higher-risk forms. While the treatment goals for lower-risk MDS are to decrease transfusion requirements and transformation into acute leukemia, the major aims for higher-risk MDS are to prolong survival and ultimately cure the patient. Although novel agents such as luspatercept and imetelstat have recently been approved as new treatment options for lower-risk MDS, hypomethylating agents currently remain the only approved non-transplant option for higher-risk MDS and are the standard of care for patients not eligible for allogeneic hematopoietic stem cell transplantation (HSCT). Combinations with other drugs as first-line treatment have to date not proven more efficacious than monotherapy in higher-risk MDS, and outcome after the failure of treatment with hypomethylating agents is poor. The only potential cure and standard of care for eligible patients is HSCT and even though the number of transplanted \u2013 especially older \u2013 MDS patients has increased over time due to better management and greater donor availability, the majority of MDS patients will not be eligible for this curative approach. Current challenges include decreasing the relapse risk, the main cause of HSCT failure. This review summarizes current knowledge on the options of transplant and non-transplant treatment approaches for these patients and demonstrate the unmet clinical need for more effective therapies.<\/jats:p>","DOI":"10.3324\/haematol.2023.284946","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T03:41:22Z","timestamp":1733370082000},"page":"339-349","source":"Crossref","is-referenced-by-count":20,"title":["Treatment of high-risk myelodysplastic syndromes"],"prefix":"10.3324","volume":"110","author":[{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"71814","doi-asserted-by":"crossref","unstructured":"Malcovati L, Hellstrom-Lindberg E, Bowen D. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013; 122(17):2943-2964.","DOI":"10.1182\/blood-2013-03-492884"},{"key":"71815","doi-asserted-by":"crossref","unstructured":"Greenberg PL, Tuechler H, Schanz J. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012; 120(12):2454-2465.","DOI":"10.1182\/blood-2012-03-420489"},{"key":"71816","unstructured":"Bernard E, Tuechler H, Greenberg PL. Molecular International Prognostic Scoring System for myelodysplastic syndromes. NEJM Evid. 2022; 1(7):EVIDoa2200008."},{"key":"71817","doi-asserted-by":"crossref","unstructured":"Tentori CA, Gregorio C, Robin M. Clinical and genomicbased decision support system to define the optimal timing of allogeneic hematopoietic stem-cell transplantation in patients with myelodysplastic syndromes. J Clin Oncol. 2024; 42(24):2873-2886.","DOI":"10.1200\/JCO.24.00649"},{"key":"71818","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022; 36(7):1703-1719.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"71819","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian RP. International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140(11):1200-1228.","DOI":"10.1182\/blood.2022015850"},{"key":"71820","doi-asserted-by":"crossref","unstructured":"Hellstrom-Lindberg ES, Kroger N. Clinical decision-making and treatment of myelodysplastic syndromes. Blood. 2023; 142(26):2268-2281.","DOI":"10.1182\/blood.2023020079"},{"key":"71821","doi-asserted-by":"crossref","unstructured":"Pfeilstocker M, Tuechler H, Sanz G. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016; 128(7):902-910.","DOI":"10.1182\/blood-2016-02-700054"},{"key":"71822","doi-asserted-by":"crossref","unstructured":"Moreno Berggren D, Folkvaljon Y, Engvall M. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS Register. Br J Haematol. 2018; 181(5):614-627.","DOI":"10.1111\/bjh.15243"},{"key":"71823","doi-asserted-by":"crossref","unstructured":"Malcovati L, Germing U, Kuendgen A. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007; 25(23):3503-3510.","DOI":"10.1200\/JCO.2006.08.5696"},{"key":"71824","doi-asserted-by":"crossref","unstructured":"Cazzola M, Malcovati L. Myelodysplastic syndromes--coping with ineffective hematopoiesis. N Engl J Med. 2005; 352(6):536-538.","DOI":"10.1056\/NEJMp048266"},{"key":"71825","doi-asserted-by":"crossref","unstructured":"de Swart L, Crouch S, Hoeks M. Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes. Haematologica. 2020; 105(3):632-639.","DOI":"10.3324\/haematol.2018.212217"},{"key":"71826","doi-asserted-by":"crossref","unstructured":"Stauder R, Yu G, Koinig KA. Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. Leukemia. 2018; 32(6):1380-1392.","DOI":"10.1038\/s41375-018-0089-x"},{"key":"71827","doi-asserted-by":"crossref","unstructured":"Mittelman M, Platzbecker U, Afanasyev B. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Lancet Haematol. 2018; 5(1):e34-e43.","DOI":"10.1016\/S2352-3026(17)30228-4"},{"key":"71828","doi-asserted-by":"crossref","unstructured":"Dickinson M, Cherif H, Fenaux P. Azacitidine with or without eltrombopag for first-line treatment of intermediateor high-risk MDS with thrombocytopenia. Blood. 2018; 132(25):2629-2638.","DOI":"10.1182\/blood-2018-06-855221"},{"key":"71829","doi-asserted-by":"crossref","unstructured":"Penack O, Peczynski C, van der Werf S. Association of serum ferritin levels before start of conditioning with mortality after alloSCT - a prospective, non-interventional study of the EBMT Transplant Complications Working Party. Front Immunol. 2020; 11:586.","DOI":"10.3389\/fimmu.2020.00586"},{"key":"71830","doi-asserted-by":"crossref","unstructured":"Essmann S, Heestermans M, Dadkhah A. Iron chelation with deferasirox suppresses the appearance of labile plasma iron during conditioning chemotherapy prior to allogeneic stem cell transplantation. Transplant Cell Ther. 2023; 29(1):42.e1-42.e6.","DOI":"10.1016\/j.jtct.2022.10.002"},{"key":"71831","doi-asserted-by":"crossref","unstructured":"Stomper J, Rotondo JC, Greve G, Lubbert M. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia. 2021; 35(7):1873-1889.","DOI":"10.1038\/s41375-021-01218-0"},{"key":"71832","doi-asserted-by":"crossref","unstructured":"Liu YC, Kwon J, Fabiani E. Demethylation and up-regulation of an oncogene after hypomethylating therapy. N Engl J Med. 2022; 386(21):1998-2010.","DOI":"10.1056\/NEJMoa2119771"},{"key":"71833","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol. 2011; 29(5):516-523.","DOI":"10.1200\/JCO.2010.31.0854"},{"key":"71834","doi-asserted-by":"crossref","unstructured":"Lubbert M, Suciu S, Baila L. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011; 29(15):1987-1996.","DOI":"10.1200\/JCO.2010.30.9245"},{"key":"71835","doi-asserted-by":"crossref","unstructured":"Silverman LR, Demakos EP, Peterson BL. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002; 20(10):2429-2440.","DOI":"10.1200\/JCO.2002.04.117"},{"key":"71836","doi-asserted-by":"crossref","unstructured":"Kornblith AB, Herndon JE 2nd, Silverman LR. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002; 20(10):2441-2452.","DOI":"10.1200\/JCO.2002.04.044"},{"key":"71837","doi-asserted-by":"crossref","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10(3):223-232.","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"71838","doi-asserted-by":"crossref","unstructured":"Greenberg PL, Stone RM, Al-Kali A. Myelodysplastic syndromes, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017; 15(1):60-87.","DOI":"10.6004\/jnccn.2017.0007"},{"key":"71839","doi-asserted-by":"crossref","unstructured":"Zeidan AM, Salimi T, Epstein RS. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?. Future Oncol. 2021; 17(36):5163-5175.","DOI":"10.2217\/fon-2021-0936"},{"key":"71840","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Griffiths EA, Steensma DP. Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study. Blood. 2020; 136(6):674-683.","DOI":"10.1182\/blood.2019004143"},{"key":"71841","doi-asserted-by":"crossref","unstructured":"Wei AH, Dohner H, Pocock C. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020; 383(26):2526-2537.","DOI":"10.1056\/NEJMoa2004444"},{"key":"71842","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Santini V, Almeida A. Phase III, randomized, placebo-controlled trial of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2021; 39(13):1426-1436.","DOI":"10.1200\/JCO.20.02619"},{"key":"71843","doi-asserted-by":"crossref","unstructured":"Nannya Y, Tobiasson M, Sato S. Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms. Blood Adv. 2023; 7(14):3624-3636.","DOI":"10.1182\/bloodadvances.2022009564"},{"key":"71844","doi-asserted-by":"crossref","unstructured":"Sekeres MA, Othus M, List AF. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017; 35(24):2745-2753.","DOI":"10.1200\/JCO.2015.66.2510"},{"key":"71845","doi-asserted-by":"crossref","unstructured":"Ades L, Girshova L, Doronin VA. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Adv. 2022; 6(17):5132-5145.","DOI":"10.1182\/bloodadvances.2022007334"},{"key":"71846","doi-asserted-by":"crossref","unstructured":"Sallman DA, Al Malki MM, Asch AS. Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study. J Clin Oncol. 2023; 41(15):2815-2826.","DOI":"10.1200\/JCO.22.01794"},{"key":"71847","doi-asserted-by":"crossref","unstructured":"Ball BJ, Famulare CA, Stein EM. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 2020; 4(13):2866-2870.","DOI":"10.1182\/bloodadvances.2020001482"},{"key":"71848","doi-asserted-by":"crossref","unstructured":"Bazinet A, Darbaniyan F, Jabbour E. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol. 2022; 9(10):e756-e765.","DOI":"10.1016\/S2352-3026(22)00216-2"},{"key":"71849","doi-asserted-by":"crossref","unstructured":"Asayama T, Tamura H, Ishibashi M. Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes. Oncotarget. 2017; 8(51):88904-88917.","DOI":"10.18632\/oncotarget.21492"},{"key":"71850","doi-asserted-by":"crossref","unstructured":"Sebert M, Stamatoullas A, Braun T. Azacitidine (AZA) combined with idarubicin in higher risk MDS - results of a phase I\/II study by the Groupe Francophone Des Myelodysplasies (GFM). Blood. 2015; 126(23):2884.","DOI":"10.1182\/blood.V126.23.2884.2884"},{"key":"71851","doi-asserted-by":"crossref","unstructured":"Ades L, Duployez N, Guerci-Bresler A. A randomised phase II study of azacitidine (AZA) alone or with lenalidomide (LEN), valproic acid (VPA) or idarubicin (IDA) in higher-risk MDS or low blast AML: GFM\u2019s \u201cpick a winner\u201d trial, with the impact of somatic mutations. Br J Haematol. 2022; 198(3):535-544.","DOI":"10.1111\/bjh.18193"},{"key":"71852","doi-asserted-by":"crossref","unstructured":"Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020; 20(3):173-185.","DOI":"10.1038\/s41577-019-0224-6"},{"key":"71853","doi-asserted-by":"crossref","unstructured":"Brunner AM, Esteve J, Porkka K. Efficacy and safety of sabatolimab (MBG) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high\/high-risk myelodysplastic syndrome (vHR\/HRMDS) and acute myeloid leukemia (AML): final analysis from a phase Ib study. Blood. 2021; 138(Supplement 1):244.","DOI":"10.1182\/blood-2021-146039"},{"key":"71854","doi-asserted-by":"crossref","unstructured":"Zeidan AM, Ando K, Rauzy O. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2024; 11(1):e38-e50.","DOI":"10.1016\/S2352-3026(23)00333-2"},{"key":"71855","unstructured":"Zeidan AM, Xiao Z, Sanz G. Primary results of the phase III STIMULUS-MDS2 study of sabatolimab + azacitidine vs placebo + azacitidine as frontline therapy for patients with higher-risk MDS or CMML-2. Hemasphere. 2024. EHA Library. Zeidan A. 06\/13\/2024;422284;S180."},{"key":"71856","doi-asserted-by":"crossref","unstructured":"Prebet T, Gore SD, Esterni B. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011; 29(24):3322-3327.","DOI":"10.1200\/JCO.2011.35.8135"},{"key":"71857","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Fenaux P, Al-Kali A. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016; 17(4):496-508.","DOI":"10.1016\/S1470-2045(16)00009-7"},{"key":"71858","doi-asserted-by":"crossref","unstructured":"Kroger N, Sockel K, Wolschke C. Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo study). J Clin Oncol. 2021; 39(30):3318-3327.","DOI":"10.1200\/JCO.20.02724"},{"key":"71859","doi-asserted-by":"crossref","unstructured":"Nakamura R, Saber W, Martens MJ. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome. J Clin Oncol. 2021; 39(30):3328-3339.","DOI":"10.1200\/JCO.20.03380"},{"key":"71860","doi-asserted-by":"crossref","unstructured":"Robin M, Porcher R, Ades L. HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome. A prospective study on behalf of SFGM-TC and GFM. Leukemia. 2015; 29(7):1496-1501.","DOI":"10.1038\/leu.2015.37"},{"key":"71861","doi-asserted-by":"crossref","unstructured":"Awada H, Gurnari C, Xie Z, Bewersdorf JP, Zeidan AM. What\u2019s next after hypomethylating agents failure in myeloid neoplasms? A rational approach. Cancers (Basel). 2023; 15(8):2248.","DOI":"10.3390\/cancers15082248"},{"key":"71862","doi-asserted-by":"crossref","unstructured":"Merz AMA, Sebert M, Sonntag J, Kubasch AS, Platzbecker U, Ades L. Phase to phase: navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes. Cancer Treat Rev. 2024; 123:102673.","DOI":"10.1016\/j.ctrv.2023.102673"},{"key":"71863","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Venugopal S, Lachowiez C. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv. 2023; 7(11):2378-2387.","DOI":"10.1182\/bloodadvances.2022008378"},{"key":"71864","doi-asserted-by":"crossref","unstructured":"DiNardo CD FJ, Watts JM. Ivosidenib (IVO) in patients with IDH1-mutant relapsed\/refractory myelodysplastic syndrome (R\/R MDS): updated enrollment of a phase 1 dose escalation and expansion study. HemaSphere. 2020:EHA Library. DiNardo C. 06\/12\/2020; 294743; EP826.","DOI":"10.1016\/S2152-2650(20)30977-0"},{"key":"71865","doi-asserted-by":"crossref","unstructured":"Sallman DA, DeZern AE, Garcia-Manero G. Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol. 2021; 39(14):1584-1594.","DOI":"10.1200\/JCO.20.02341"},{"key":"71866","doi-asserted-by":"crossref","unstructured":"Mishra A, Tamari R, DeZern AE. Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2022; 40(34):3985-3993.","DOI":"10.1200\/JCO.22.00181"},{"key":"71867","doi-asserted-by":"crossref","unstructured":"Wattel E, De Botton S, Luc Lai J. Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders. Br J Haematol. 1997; 98(4):983-991.","DOI":"10.1046\/j.1365-2141.1997.2973114.x"},{"key":"71868","doi-asserted-by":"crossref","unstructured":"Bally C, Ades L, Renneville A. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Leuk Res. 2014; 38(7):751-755.","DOI":"10.1016\/j.leukres.2014.03.012"},{"key":"71869","doi-asserted-by":"crossref","unstructured":"de Witte T, Suciu S, Verhoef G. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood. 2001; 98(8):2326-2331.","DOI":"10.1182\/blood.V98.8.2326"},{"key":"71870","doi-asserted-by":"crossref","unstructured":"Peterlin P, Le Bris Y, Turlure P. CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Haematol. 2023; 10(7):e521-e529.","DOI":"10.1016\/S2352-3026(23)00090-X"},{"key":"71871","doi-asserted-by":"crossref","unstructured":"Cutler CS, Lee SJ, Greenberg P. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004; 104(2):579-585.","DOI":"10.1182\/blood-2004-01-0338"},{"key":"71872","doi-asserted-by":"crossref","unstructured":"Alessandrino EP, Porta MG, Malcovati L. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Am J Hematol. 2013; 88(7):581-588.","DOI":"10.1002\/ajh.23458"},{"key":"71873","doi-asserted-by":"crossref","unstructured":"Della Porta MG, Jackson CH, Alessandrino EP. Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. Leukemia. 2017; 31(11):2449-2457.","DOI":"10.1038\/leu.2017.88"},{"key":"71874","doi-asserted-by":"crossref","unstructured":"Onida F, Brand R, van Biezen A. Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. Haematologica. 2014; 99(10):1582-1590.","DOI":"10.3324\/haematol.2014.106880"},{"key":"71875","doi-asserted-by":"crossref","unstructured":"van Gelder M, de Wreede LC, Schetelig J. Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia. Leukemia. 2013; 27(4):879-888.","DOI":"10.1038\/leu.2012.297"},{"key":"71876","doi-asserted-by":"crossref","unstructured":"Della Porta MG, Galli A, Bacigalupo A. Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2016; 34(30):3627-3637.","DOI":"10.1200\/JCO.2016.67.3616"},{"key":"71877","doi-asserted-by":"crossref","unstructured":"Lindsley RC, Saber W, Mar BG. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017; 376(6):536-547.","DOI":"10.1056\/NEJMoa1611604"},{"key":"71878","doi-asserted-by":"crossref","unstructured":"Yoshizato T, Nannya Y, Atsuta Y. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood. 2017; 129(17):2347-2358.","DOI":"10.1182\/blood-2016-12-754796"},{"key":"71879","doi-asserted-by":"crossref","unstructured":"Gurnari C, Gagelmann N, Badbaran A. Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M. Leukemia. 2023; 37(3):717-719.","DOI":"10.1038\/s41375-023-01820-4"},{"key":"71880","doi-asserted-by":"crossref","unstructured":"Sauta E, Robin M, Bersanelli M. Real-world validation of Molecular International Prognostic Scoring System for myelodysplastic syndromes. J Clin Oncol. 2023; 41(15):2827-2842.","DOI":"10.1200\/JCO.22.01784"},{"key":"71881","doi-asserted-by":"crossref","unstructured":"Atallah E, Logan B, Chen M. Comparison of patient age groups in transplantation for myelodysplastic syndrome: the Medicare Coverage With Evidence Development study. JAMA Oncol. 2020; 6(4):486-493.","DOI":"10.1001\/jamaoncol.2019.5140"},{"key":"71882","doi-asserted-by":"crossref","unstructured":"Niederwieser C, Kroger N. Hematopoietic cell transplantation (HCT) in MDS patients of older age. Leuk Lymphoma. 2024; 65(5):570-584.","DOI":"10.1080\/10428194.2024.2307444"},{"key":"71883","doi-asserted-by":"crossref","unstructured":"DeFilipp Z, Ciurea SO, Cutler C. Hematopoietic cell transplantation in the management of myelodysplastic syndrome: an evidence-based review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. Transplant Cell Ther. 2023; 29(2):71-81.","DOI":"10.1016\/j.jtct.2022.11.014"},{"key":"71884","doi-asserted-by":"crossref","unstructured":"Versluis J, Saber W, Tsai HK. Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 study. J Clin Oncol. 2023; 41(28):4497-4510.","DOI":"10.1200\/JCO.23.00866"},{"key":"71885","doi-asserted-by":"crossref","unstructured":"Kennedy AL, Shimamura A. Genetic predisposition to MDS: clinical features and clonal evolution. Blood. 2019; 133(10):1071-1085.","DOI":"10.1182\/blood-2018-10-844662"},{"key":"71886","doi-asserted-by":"crossref","unstructured":"Carre M, Porcher R, Finke J. Role of age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in myelodysplastic patients undergoing an allotransplant: a retrospective study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2020; 26(3):451-457.","DOI":"10.1016\/j.bbmt.2019.10.015"},{"key":"71887","doi-asserted-by":"crossref","unstructured":"Penack O, Peczynski C, Mohty M. Association of preexisting comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT. Bone Marrow Transplant. 2022; 57(2):183-190.","DOI":"10.1038\/s41409-021-01502-8"},{"key":"71888","doi-asserted-by":"crossref","unstructured":"Della Porta MG, Alessandrino EP, Bacigalupo A. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood. 2014; 123(15):2333-2342.","DOI":"10.1182\/blood-2013-12-542720"},{"key":"71889","doi-asserted-by":"crossref","unstructured":"Shaffer BC, Ahn KW, Hu ZH. Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. J Clin Oncol. 2016; 34(16):1864-1871.","DOI":"10.1200\/JCO.2015.65.0515"},{"key":"71890","doi-asserted-by":"crossref","unstructured":"Gagelmann N, Eikema DJ, Stelljes M. Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. Haematologica. 2019; 104(5):929-936.","DOI":"10.3324\/haematol.2018.200808"},{"key":"71891","doi-asserted-by":"crossref","unstructured":"de Witte T, Bowen D, Robin M. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017; 129(13):1753-1762.","DOI":"10.1182\/blood-2016-06-724500"},{"key":"71892","doi-asserted-by":"crossref","unstructured":"Niederwieser C, Kroger N. Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome. Best Pract Res Clin Haematol. 2021; 34(4):101332.","DOI":"10.1016\/j.beha.2021.101332"},{"key":"71893","doi-asserted-by":"crossref","unstructured":"Kroger N. Induction, bridging, or straight ahead: the ongoing dilemma of allografting in advanced myelodysplastic syndrome. Biol Blood Marrow Transplant. 2019; 25(8):e247-e249.","DOI":"10.1016\/j.bbmt.2019.06.016"},{"key":"71894","doi-asserted-by":"crossref","unstructured":"Scheid C, Eikema DJ, van Gelder M. Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?. Blood. 2024; 144(4):445-456.","DOI":"10.1182\/blood.2023022273"},{"key":"71895","doi-asserted-by":"crossref","unstructured":"Martino R, Iacobelli S, Brand R. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006; 108(3):836-846.","DOI":"10.1182\/blood-2005-11-4503"},{"key":"71896","doi-asserted-by":"crossref","unstructured":"Kroger N, Iacobelli S, Franke GN. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial). J Clin Oncol. 2017; 35(19):2157-2164.","DOI":"10.1200\/JCO.2016.70.7349"},{"key":"71897","doi-asserted-by":"crossref","unstructured":"Scott BL, Pasquini MC, Logan BR. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017; 35(11):1154-1161.","DOI":"10.1200\/JCO.2016.70.7091"},{"key":"71898","doi-asserted-by":"crossref","unstructured":"Beelen DW, Trenschel R, Stelljes M. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. 2020; 7(1):e28-e39.","DOI":"10.1016\/S2352-3026(19)30157-7"},{"key":"71899","unstructured":"Oran B, Ahn KW, Fretham C. Fludarabine and melphalan compared with reduced doses of busulfan and fludarabine improve transplantation outcomes in older patients with myelodysplastic syndromes. Transplant Cell Ther. 2021; 27(11):921.e1-921.e10."},{"key":"71900","doi-asserted-by":"crossref","unstructured":"Grunwald MR, Zhang MJ, Elmariah H. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. Blood Adv. 2021; 5(4):975-983.","DOI":"10.1182\/bloodadvances.2020003654"},{"key":"71901","doi-asserted-by":"crossref","unstructured":"Duncavage EJ, Jacoby MA, Chang GS. Mutation clearance after transplantation for myelodysplastic syndrome. N Engl J Med. 2018; 379(11):1028-1041.","DOI":"10.1056\/NEJMoa1804714"},{"key":"71902","doi-asserted-by":"crossref","unstructured":"Tobiasson M, Pandzic T, Illman J. Patient-specific measurable residual disease markers predict outcome in patients with myelodysplastic syndrome and related diseases after hematopoietic stem-cell transplantation. J Clin Oncol. 2024; 42(12):1378-1390.","DOI":"10.1200\/JCO.23.01159"},{"key":"71903","doi-asserted-by":"crossref","unstructured":"Oran B, de Lima M, Garcia-Manero G. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020; 4(21):5580-5588.","DOI":"10.1182\/bloodadvances.2020002544"},{"key":"71904","doi-asserted-by":"crossref","unstructured":"Fathi AT, Kim HT, Soiffer RJ. Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies. Blood Adv. 2022; 6(22):5857-5865.","DOI":"10.1182\/bloodadvances.2022008632"},{"key":"71905","doi-asserted-by":"crossref","unstructured":"Platzbecker U, Middeke JM, Sockel K. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018; 19(12):1668-1679.","DOI":"10.1016\/S1470-2045(18)30580-1"},{"key":"71906","doi-asserted-by":"crossref","unstructured":"Schroeder T, Stelljes M, Christopeit M. Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-trial. Haematologica. 2023; 108(11):3001-3010.","DOI":"10.3324\/haematol.2022.282570"},{"key":"71907","doi-asserted-by":"crossref","unstructured":"Guisnel C, Schirmer L, Morisset S. On behalf of the SFGM-TC: prophylactic donor lymphocyte infusion in patients treated with allogeneic stem-cell transplantation for high-risk myelodysplastic syndrome and acute myeloid leukemia. Acta Haematol. 2023; 146(3):230-239.","DOI":"10.1159\/000528184"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11858\/77878","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11858\/78029","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11858\/77878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:48Z","timestamp":1794046068000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":94,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284946","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,5]]}}}